Advertisement
CELZ vs GNPX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and GNPX is a Hold.
CELZ in downward trend: 10-day moving average moved below 50-day moving average on September 17, 2026
The 10-day moving average for CELZ crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELZ as a result. In 87 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CELZ turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
CELZ moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CELZ's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELZ advanced for three days, in 200 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.650) is normal, around the industry mean (2.835). P/E Ratio (-0.361) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for GNPX turns negative, indicating new downward trend
GNPX saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 71 similar instances where the indicator turned negative. In 67 of the 71 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.117) is normal, around the industry mean (2.835). P/E Ratio (0.061) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CELZ | GNPX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 48 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | 97 | |
P/E GROWTH RATING 1..100 | 20 | 96 | |
SEASONALITY SCORE 1..100 | 85 | 24 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX's Valuation (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CELZ (85) in the null industry. This means that GNPX’s stock grew somewhat faster than CELZ’s over the last 12 months.
GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CELZ (100) in the null industry. This means that GNPX’s stock grew similarly to CELZ’s over the last 12 months.
CELZ's SMR Rating (98) in the null industry is in the same range as GNPX (100) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew similarly to GNPX’s over the last 12 months.
CELZ's Price Growth Rating (86) in the null industry is in the same range as GNPX (97) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew similarly to GNPX’s over the last 12 months.
CELZ's P/E Growth Rating (20) in the null industry is significantly better than the same rating for GNPX (96) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew significantly faster than GNPX’s over the last 12 months.
| CELZ | GNPX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 73% |
| Stochastic ODDS (%) | 4 days ago 77% | 4 days ago 88% |
| Momentum ODDS (%) | 4 days ago 88% | 4 days ago 90% |
| MACD ODDS (%) | 4 days ago 88% | N/A |
| TrendWeek ODDS (%) | 4 days ago 87% | 4 days ago 90% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 90% |
| Advances ODDS (%) | 18 days ago 85% | 12 days ago 76% |
| Declines ODDS (%) | 6 days ago 85% | 4 days ago 90% |
| BollingerBands ODDS (%) | 6 days ago 90% | 4 days ago 77% |
| Aroon ODDS (%) | 4 days ago 85% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CELZ’s FA Score shows that 1 FA rating(s) are green while GNPX’s FA Score has 0 green FA rating(s).
- CELZ’s FA Score: 1 green, 4 red.
- GNPX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CELZ’s TA Score shows that 4 TA indicator(s) are bullish while GNPX’s TA Score has 4 bullish TA indicator(s).
- CELZ’s TA Score: 4 bullish, 6 bearish.
- GNPX’s TA Score: 4 bullish, 3 bearish.
Price Growth
CELZ (@Biotechnology) experienced а -11.63% price change this week, while GNPX (@Biotechnology) price change was -22.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
Reported Earning Dates
CELZ is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Biotechnology (-7.77% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CELZ and
Correlation & Price change
A.I.dvisor tells us that CELZ and WVE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELZ and WVE's prices will move in lockstep.
| Ticker / NAME | Correlation To CELZ | 1D Price Change % | ||
|---|---|---|---|---|
| CELZ | 100% | -9.39% | ||
| WVE - CELZ | 30% Poorly correlated | -1.88% | ||
| TRDA - CELZ | 29% Poorly correlated | -8.58% | ||
| GNPX - CELZ | 28% Poorly correlated | -7.86% | ||
| IOVA - CELZ | 26% Poorly correlated | -7.47% | ||
| ACET - CELZ | 26% Poorly correlated | -11.09% | ||
More | ||||
GNPX and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
|---|---|---|---|---|
| GNPX | 100% | -7.86% | ||
| CANF - GNPX | 93% Closely correlated | -4.86% | ||
| APVO - GNPX | 86% Closely correlated | -4.71% | ||
| ICU - GNPX | 82% Closely correlated | -5.23% | ||
| MLEC - GNPX | 76% Closely correlated | -10.16% | ||
| LONA - GNPX | 76% Closely correlated | -1.70% | ||
More | ||||